Carter Gould

“Maybe just to go back to the bridge program, have you had conversations with the admin or the various Plan D sponsors that give you confidence this program will either be extended or balance will be revisited in a different iteration, I guess, to the point?”

“You've got a number of small cell lung cancer studies expected to read out over 27 and 28. I was hoping you could talk about your confidence and the relevancy of these studies in light of the IMDELTRA frontline data and if that augurs any sort of changes to your strategy.”

“Maybe let's start on the pipeline on MK3000. How are you thinking ultimately about dosing? The one-year Brunella data is likely not going to inform much on duration interval, and the Lucentis comparison is going to leave lots of questions unresolved.”

“And maybe to change it up a bit, for George, as you spoke about the co-injection of C5 with the Flibercept, should we think about that as more of a convenience play sort of with the co-administration or potentially more of, I guess, a label expansion as you think about potentially preventing wet AMD, I guess, forming…”